News
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18 Mar 24
News
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
26 Feb 24
Equities, News, Markets, ETFs
Goldman Sachs Downgrades Intellia Therapeutics to Neutral, Announces $32 Price Target
23 Feb 24
News, Downgrades, Price Target, Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Raises Price Target to $73
23 Feb 24
News, Price Target, Analyst Ratings
Intellia Therapeutics Q4 EPS $(1.46) Misses $(1.45) Estimate, Sales $(1.92M) May Not Be Comparable To $12.83M Estimate
22 Feb 24
Earnings, News
Earnings Scheduled For February 22, 2024
22 Feb 24
Earnings
A Preview Of Intellia Therapeutics's Earnings
21 Feb 24
Earnings
Intellia Therapeutics, ReCode Therapeutics Enter Strategic Collaboration To Develop Novel Genomic Medicines For Treatment Of Cystic Fibrosis; No Financial Terms Disclosed
15 Feb 24
News, Contracts
Wolfe Research Initiates Coverage On Intellia Therapeutics with Peer Perform Rating
15 Feb 24
News, Initiation, Analyst Ratings
Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock
5 Feb 24
Equities, News, Markets, ETFs
Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company
1 Feb 24
Equities, News, Markets, ETFs
Intellia Therapeutics Reveals Publication Of Interim Phase 1 Data For NTLA-2002 In Patients With Hereditary Angioedema In The New England Journal Of Medicine
31 Jan 24
News
Press releases
Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
2 Apr 24
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
18 Mar 24
Press Releases
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
22 Feb 24
Earnings, Press Releases
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
15 Feb 24
Health Care, Press Releases
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates
14 Feb 24
News, Press Releases
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine
31 Jan 24
Health Care, Press Releases
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
24 Jan 24
Press Releases